Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.00%205.101.2%$477.70m
GILDGilead Sciences, Inc.
0.91%75.510.9%$401.46m
BIIBBiogen Inc.
1.22%345.411.3%$352.23m
CELGCelgene Corporation
-0.66%87.721.2%$341.18m
ILMNIllumina, Inc.
0.52%358.163.5%$248.76m
REGNRegeneron Pharmaceuticals, Inc.
0.78%390.282.6%$232.51m
VRTXVertex Pharmaceuticals Incorporated
-0.24%180.081.9%$168.98m
EXASExact Sciences Corporation
1.72%76.2825.3%$162.68m
SRPTSarepta Therapeutics, Inc.
-3.43%147.5916.4%$129.44m
AAgilent Technologies, Inc.
-0.58%70.721.5%$124.93m
VKTXViking Therapeutics, Inc.
-4.06%18.200.9%$115.92m
ALXNAlexion Pharmaceuticals, Inc.
-2.10%121.992.0%$114.40m
NKTRNektar Therapeutics
0.96%59.005.6%$106.74m
BMRNBioMarin Pharmaceutical Inc.
-2.55%97.844.4%$97.41m
ALNYAlnylam Pharmaceuticals, Inc
-0.67%94.579.7%$93.14m

Company Profile

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.